Day: September 12, 2023

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023. “The issuance of this patent is an important milestone in protecting the composition of matter and methods of treatment for our BDC-3042 clinical candidate,” explained Justin A. Kenkel, Ph.D., BDC-3042 co-inventor and Principal Scientist at Bolt Biotherapeutics. “This patent covers antibodies with a novel mechanism of action that leverages Dectin-2 agonism to repolarize tumor-associated macrophages into immunostimulatory,...

Series of standard tests for building materials viewed as important step in commercialization process BOCA RATON, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) — Xeriant, Inc. (OTCQB: XERI) (“Xeriant” or “the Company”), a Company dedicated to the discovery, development, and commercialization of aerospace technologies and advanced materials, announces today that it has engaged two leading accredited testing agencies to perform a series of globally-recognized tests to assess the physical and mechanical properties of NEXBOARDTM, an eco-friendly, patent-pending composite building panel made primarily from recycled plastic and cardboard that is resistant to fire, water, insects and mold. Viewed as a significant component in the commercialization process, the third-party testing will measure and certify the critical safety and performance features...

Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancerNEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced that data from a pre-defined interim analysis related to the lung cohort of the Phase 2 basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as first-line therapy were presented today at the IASLC 2023 World Conference on Lung Cancer (WCLC). Jonathan Riess, MD, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting...

Tel Aviv, Israel, Sept. 12, 2023 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that on September 5, 2023, AI Systems Ltd. (“AI Systems”) approved the conversion of a $1,240 thousand  (4.75 million NIS) convertible loan of the Company into shares of AI Systems. Following the conversion, Medigus will hold a 36% stake in AI Systems and become its largest shareholder. AI Systems, a technology company traded on the Tel Aviv Stock Exchange (TASE), is in negotiations to merge new activity and further expand its technological endeavors. This conversion of the convertible loan to shares solidifies Medigus’ commitment to diversify its investments with AI – based technologies...

• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of Phase 2 clinical data by collaborators at the Yale Cancer Center demonstrating clinical benefit in patients with advanced, PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) treated with a combination regimen of NC318, a Siglec-15 (S15) monoclonal antibody (mAb), and pembrolizumab, an anti-PD-1 antibody. NC318 is a humanized IgG1 mAb against S15 that blocks interactions of S15 with myeloid...

nCino enhances efficiency to support growth ambitions while helping ensure data security at the Tokyo-based financial institution TOKYO and WILMINGTON, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that The Nomura Trust & Banking Co., Ltd. (Nomura Trust), a Japanese trust bank and wholly-owned subsidiary of Nomura Holdings, Inc., has successfully implemented and is live on the nCino Cloud Banking Platform. This development marks a significant step forward in Nomura Trust’s modernization journey. Established in 1993, Nomura Trust provides trust and banking services, and currently has over ¥50 billion in capitalization. The bank recognized the need to modernize its operations to better serve its customers in the...

LOUISVILLE, Ky., Sept. 12, 2023 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today announced that Ja Hillebrand, Chairman and CEO and T. Clay Stinnett, EVP and CFO will participate in the Stephens 2023 Annual Bank Forum to be held September 19th and 20th, and will participate in a series of meetings with institutional investors. Management’s discussion materials to be used at this conference will be posted to the investor section of the Company’s website, www.syb.com, on or before September 19, 2023. Louisville, Kentucky-based Stock Yards Bancorp, Inc., with $7.73 billion in assets, was incorporated...

MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations participating in medical research. Syneos Health is evolving its patient recruitment capabilities to further address unmet sponsor, site and patient needs. Through its collaboration with the Oracle Cerner LHN, Syneos Health’s objective is to improve performance throughout the entire clinical trial lifecycle, with a strong emphasis on clinical...

CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO) and Head of Business Development (BD), effective immediately. In this capacity, in addition to his current BD responsibilities, Dr. Vasanthavada will oversee all aspects of commercial strategy, planning and operations as Abeona prepares for a potential launch of EB-101, its investigational, genetically engineered autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Dr. Vasanthavada is a seasoned commercial executive bringing over 20 years of experience with leadership roles in sales, marketing, and market access in the life sciences industry, including launch experience with autologous cell therapies. Over...

nCino enhances efficiency to support growth ambitions while helping ensure data security at the Tokyo-based financial institution TOKYO and WILMINGTON, Del., Sept. 12, 2023 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that The Nomura Trust & Banking Co., Ltd. (Nomura Trust), a Japanese trust bank and wholly-owned subsidiary of Nomura Holdings, Inc., has successfully implemented and is live on the nCino Cloud Banking Platform. This development marks a significant step forward in Nomura Trust’s modernization journey. Established in 1993, Nomura Trust provides trust and banking services, and currently has over ¥50 billion in capitalization. The bank recognized the need to modernize its operations to better serve its customers in the...